Market Overview - The biopharmaceutical sector experienced a decline of 0.57% on October 22, with Aopumai leading the drop [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Wendi Pharmaceutical (688488) with a closing price of 14.77, up 4.01% [1] - Dongbao Bio (300239) at 5.78, up 2.66% [1] - Jinke (688670) at 17.03, up 2.59% [1] - Major decliners included: - Aopumai (688293) at 55.19, down 4.40% [2] - Wofu Bio (300357) at 31.63, down 3.18% [2] - Sanofi (688336) at 59.60, down 2.39% [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 192 million yuan from institutional investors, while retail investors contributed a net inflow of 53.82 million yuan [2] - Specific stock capital flows included: - Te Bao Bio (688278) with a net inflow of 19.00 million yuan from institutional investors [3] - Hualan Bio (002007) with a net inflow of 12.05 million yuan from institutional investors [3] - Aopumai (688293) with a net outflow of 4.40% from institutional investors [3]

Group 1 - The core viewpoint of the article highlights the active performance of plant-based meat concept stocks in the A-share market, with notable gains in companies like SuoBao Protein and Shuangta Food reaching the daily limit, while Dongbao Bio and Hao Xiang Ni also saw significant increases [1] - Beyond Meat, the first plant-based meat stock in the US market, experienced a dramatic surge, with a 127% increase on Monday followed by a further 146.26% rise on Tuesday, resulting in a total price increase of over 450% in just two trading days [1]

Core Viewpoint - Dongbao Biological announced that it will not adjust the conversion price of its convertible bonds despite triggering conditions for a downward adjustment due to stock prices being below 90% of the conversion price for 15 trading days [1] Group 1: Company Actions - The company’s stock price has been below the conversion price of 6.63 yuan per share for 15 trading days, triggering the conditions for a downward adjustment of the "Dongbao Convertible Bonds" [1] - The board of directors held a meeting on October 15, 2025, and decided not to adjust the conversion price of the "Dongbao Convertible Bonds" [1] - From October 16, 2025, to April 15, 2026, if the conditions for a downward adjustment are triggered again, the company will not propose a downward adjustment plan [1] Group 2: Future Considerations - After April 16, 2026, if the conditions for a downward adjustment are triggered again, the board will convene to decide whether to exercise the right to adjust the conversion price [1]

Group 1 - The company Dongbao Biological announced that its 13th meeting of the 9th board of directors will be held on October 15, 2025, at its headquarters in Baotou [1] - The meeting will review the proposal regarding not adjusting the conversion price of "Dongbao Convertible Bonds" [1]

| 证券代码：300239 | 证券简称：东宝生物 | 公告编号：2025-066 | | --- | --- | --- | | 债券代码：123214 | 债券简称：东宝转债 | | 一、可转换公司债券基本情况 1、可转换公司债券发行情况 经中国证券监督管理委员会出具的《关于同意包头东宝生物技术股份有限公司 向不特定对象发行可转换公司债券注册的批复》(证监许可﹝2023﹞1517 号)同意注 册，公司向不特定对象发行 45,500.00 万元可转换为公司 A 股股票的可转换公司债 券，每张面值为人民币 100 元，共计 4,550,000 张。本次发行可转换公司债券募集 资金总额为 45,500.00 万元，扣除发行费用人民币 1,273.66 万元(不含税金额)后， 实际募集资金净额为人民币 44,226.34 万元。上述募集资金已于 2023 年 8 月 4 日全 部到账。信永中和会计师事务所(特殊普通合伙)已对本次发行的募集资金到账情况 进行验资，并出具了"XYZH/2023JNAA1B0384"号《向不特定对象发行可转换公司债 券募集资金验资报告》。 2、可转换公司债券上市情况 经深圳证券交易所同 ...

| 证券代码：300239 | 证券简称：东宝生物 | 公告编号：2025-065 | | --- | --- | --- | | 债券代码：123214 | 债券简称：东宝转债 | | 转股价格向下修正权利。 表决结果：7票同意，0票反对，0票弃权。 本议案获得表决通过。 包头东宝生物技术股份有限公司 第九届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 包头东宝生物技术股份有限公司(以下简称"公司")第九届董事会第十三次 会议于 2025 年 10 月 15 日 15:30 在包头稀土高新区黄河大街 46 号包头东宝生物 技术股份有限公司会议室召开。本次会议由公司董事长王爱国先生召集并主持。 会议通知于 2025 年 10 月 15 日以电话、口头或直接送达等形式发出。本次会议 采取现场及通讯表决的方式召开，应参加本次会议表决的董事 7 人，实际参加 本次会议表决的董事为 7 人。其中，现场出席 2 人，通讯出席 5 人，董事长王爱 国先生、董事兼副总经理刘燕女士、独立董事任斌先生、独立董事额尔敦陶克涛 先 ...

Core Viewpoint - Dongbao Bio (300239.SZ) has announced a share buyback program, repurchasing a total of 10,573,400 shares, which represents 1.7812% of the company's current total share capital, in compliance with relevant regulations [1] Summary by Category - **Share Buyback Details** - The company has repurchased shares through a special securities account via centralized bidding [1] - The highest transaction price was 5.71 CNY per share, while the lowest was 4.59 CNY per share [1] - The total amount spent on the buyback was 56,110,096.00 CNY (excluding transaction fees) [1]

关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：300239 证券简称：东宝生物 公告编号：2025-063 债券代码：123214 债券简称：东宝转债 包头东宝生物技术股份有限公司 (1)自可能对本公司证券及其衍生品种交易价格产生重大影响的重大事项发 生之日或者在决策过程中，至依法披露之日内； (2)中国证监会及深圳证券交易所规定的其他情形。 包头东宝生物技术股份有限公司(以下简称"东宝生物"或"公司")于2025 年1月3日召开第九届董事会第八次会议、第九届监事会第七次会议，审议通过了 《关于回购公司股份方案的议案》，使用公司自有资金和/或自筹资金以集中竞 价交易方式或法律法规允许的方式回购公司已发行的人民币普通股(A股)股票， 回购的公司股份用于实施员工持股计划或股权激励。本次回购股份不低于人民币 5,000万元(含)，且不超过人民币10,000万元(含)，具体回购资金总额以回购期限 届满时或者回购股份实施完毕时实际回购股份使用的成交资金总额为准。本次回 购价格不超过人民币8.00元/股(含)，本次回购股份的实施期限 ...

3、截至 2025 年第三季度末，公司剩余可转债为 4,549,670 张，剩余票面总金额为 454,967,000 元人民币。 根据《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上市公司自律监 管指引第15号——可转换公司债券》的有关规定，包头东宝生物技术股份有限公司(以 下简称"公司"或"东宝生物")现将2025年第三季度可转换公司债券转股及公司总股本变 化情况公告如下： 一、可转换公司债券发行及上市情况 | 证券代码：300239 | 证券简称：东宝生物 | 公告编号：2025-064 | | --- | --- | --- | | 债券代码：123214 | 债券简称：东宝转债 | | 包头东宝生物技术股份有限公司 关于 2025 年第三季度可转换公司债券转股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、"东宝转债"(债券代码：123214)的转股期限为2024年2月5日至2029年7月30日； 最新有效的转股价格为6.63元/股。 2、2025年第三季度，"东宝转债"未发生转股情况。 (一)可转债发行情况 经中国 ...

Group 1 - The company announced that from September 17, 2025, to September 30, 2025, its stock price has been below the current conversion price of 6.63 yuan per share for ten trading days, which is 90% of the conversion price [1] - This situation is expected to trigger the downward adjustment condition for the "Dongbao Convertible Bonds" conversion price [1] - If the conversion price adjustment condition is triggered, the company will follow the provisions of the "Prospectus" to timely fulfill subsequent review procedures and information disclosure obligations [1]